Daiichi Sankyo multi-target oncology collaboration
exploratoryDiscover and advance novel oncology therapeutics against oncology programs of interest to Daiichi Sankyo using General Proximity's OmniTAC platform.
Apply the proprietary OmniTAC induced-proximity discovery platform to identify small molecules that precisely and selectively modify disease-driving proteins in oncology.
Multi-target collaboration with Daiichi Sankyo Research Institute in Boston announced on November 13, 2025.